Cargando…

Disparities in Guideline-Concordant Initial Systemic Treatment in Women with HER2-Negative Metastatic Breast Cancer: A SEER-Medicare Analysis

BACKGROUND: Data on guideline-concordant initial systemic treatment among women with HER2-negative metastatic breast cancer (MBC) are limited. We determined the proportion of women with HER2-negative MBC who received guideline-concordant treatment and the extent to which independent variables explai...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vyas, Ami, Gabriel, Meghan, Kurian, Sobha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053132/ https://www.ncbi.nlm.nih.gov/pubmed/33880062 http://dx.doi.org/10.2147/BCTT.S295526

Ejemplares similares

Racial Disparities in Breast Cancer Treatments and Adverse Events in the SEER-Medicare Data
por: Wieder, Robert, et al.
Publicado: (2023)

Trends in Sociodemographic Disparities in Colorectal Cancer Staging and Survival: A SEER–Medicare Analysis
por: Liang, Peter S., et al.
Publicado: (2020)

Disparities in cancer-specific and overall survival in black women with endometrial cancer: A Medicare-SEER study
por: Saris, Daniel H., et al.
Publicado: (2022)

Using Pointwise Mutual Information for Breast Cancer Health Disparities Research With SEER-Medicare Claims
por: Egleston, Brian L., et al.
Publicado: (2023)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Comparison of SEER Treatment Data With Medicare Claims
por: Noone, Anne-Michelle, et al.
Publicado: (2016)

Racial disparities in guideline-concordant cancer care and mortality in the United States
por: Fang, Penny, et al.
Publicado: (2018)

Disparities in long-term radiographic follow-up after cystectomy for bladder cancer: Analysis of the SEER-Medicare database
por: Alanee, Shaheen, et al.
Publicado: (2016)

Risk factors for venous thromboembolism in metastatic colorectal cancer with contemporary treatment: A SEER‐Medicare analysis
por: Ades, Steven, et al.
Publicado: (2022)

Overview of the SEER—Medicare Health Outcomes Survey Linked Dataset
por: Ambs, Anita, et al.
Publicado: (2008)

Evaluating anthracycline + taxane versus taxane-based chemotherapy in older women with node-negative triple-negative breast cancer: a SEER-Medicare study
por: Schreiber, Anna R., et al.
Publicado: (2021)

Hepatocellular Carcinoma Survival by Etiology: A SEER‐Medicare Database Analysis
por: Brar, Gagandeep, et al.
Publicado: (2020)

Opportunities for Personalizing Colorectal Cancer Care: An Analysis of SEER-Medicare Data
por: Rivers, Zachary T., et al.
Publicado: (2022)

Impact of timing to initiate adjuvant therapy on survival of elderly glioblastoma patients using the SEER-Medicare and national cancer databases
por: Zhu, Ping, et al.
Publicado: (2023)

A Cross-Sectional Study of Disparities in Screening Guideline Concordance Within a Student-Run Clinic
por: Wilson, Philip A., et al.
Publicado: (2022)

Associations between initiating antihypertensive regimens on stage I–III colorectal cancer outcomes: A Medicare SEER cohort analysis
por: Balkrishnan, Rajesh, et al.
Publicado: (2021)

Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods
por: Aly, Abdalla, et al.
Publicado: (2015)

Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis
por: Scarton, Lisa, et al.
Publicado: (2022)

Prediagnostic CT or MRI Utilization and Outcomes in Hepatocellular Carcinoma: SEER-Medicare Database Analysis
por: Karim, Mohammad A., et al.
Publicado: (2023)

Adjuvant treatment for the elderly patient with resected gallbladder cancer: a SEER-Medicare analysis
por: de Savornin Lohman, Elise, et al.
Publicado: (2022)

Script Concordance Tests: Guidelines for Construction
por: Fournier, Jean Paul, et al.
Publicado: (2008)

Data concordance between ESRD Medical Evidence Report and Medicare claims: is there any improvement?
por: Mu, Yi, et al.
Publicado: (2018)

Identifying a Population Living With Alzheimer’s: Concordance Between Medicare Claims and Survey Reports
por: Akincigil, Ayse, et al.
Publicado: (2020)

Negation and Negative Concord in Georgian Sign Language
por: Pfau, Roland, et al.
Publicado: (2022)

Treatment practice in the elderly patient with chronic lymphocytic leukemia—analysis of the combined SEER and Medicare database
por: Satram-Hoang, Sacha, et al.
Publicado: (2014)

Epidemiology and outcomes of previously undiagnosed diabetes in older women with breast cancer: an observational cohort study based on SEER-Medicare
por: Griffiths, Robert I, et al.
Publicado: (2012)

ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
por: Urso, Loredana, et al.
Publicado: (2021)

The Medicare Home Health Initiative
por: Vladeck, Bruce C., et al.
Publicado: (1994)

Novel Opioid Safety Clinic Initiative to Deliver Guideline-Concordant Chronic Opioid Therapy in Primary Care
por: Binswanger, Ingrid A., et al.
Publicado: (2018)

Racial disparities in pancreatic neuroendocrine tumors survival: a SEER study
por: Zhou, Huaqiang, et al.
Publicado: (2017)

Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: A population-based study in SEER-Medicare
por: Petrick, Jessica L., et al.
Publicado: (2017)

SUN-626 Survival of Patients with Gastroenteropancreatic Neuroendocrine Tumors and Diabetes Mellitus in a Seer-Medicare Cohort
por: Thapi, Sahityasri, et al.
Publicado: (2020)

Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
por: Bishnoi, Rohit, et al.
Publicado: (2020)

Lack of survival advantage among re-resected elderly glioblastoma patients: a SEER-Medicare study
por: Goldman, Debra A, et al.
Publicado: (2020)

Health-care access dimensions and ovarian cancer survival: SEER-Medicare analysis of the ORCHiD study
por: Montes de Oca, Mary Katherine, et al.
Publicado: (2023)

Nobody Doesn’t Like Negative Concord
por: Maldonado, Mora, et al.
Publicado: (2021)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Histologic heterogeneity predicts patient prognosis of HER2‐positive metastatic breast cancer: A retrospective study based on SEER database
por: Wang, Yajie, et al.
Publicado: (2023)

Assessment of Guideline-Nonconcordant Radiotherapy in Medicare Beneficiaries With Metastatic Cancer Near the End of Life, 2015-2017
por: Santos, Patricia Mae G., et al.
Publicado: (2022)

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer
por: Shah, Ami N, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q7gr2uoe03mnqp3a54irovdcah